Merus BV - Asset Resilience Ratio
Merus BV (MRUS) has an Asset Resilience Ratio of 29.69% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Merus BV's Asset Resilience Ratio has changed over time. Check Merus BV strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Merus BV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MRUS market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $229.19 Million | 29.69% |
| Total Liquid Assets | $229.19 Million | 29.69% |
Asset Resilience Insights
- Very High Liquidity: Merus BV maintains exceptional liquid asset reserves at 29.69% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Merus BV Industry Peers by Asset Resilience Ratio
Compare Merus BV's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
|
Sk Biopharmaceuticals Co Ltd
KO:326030 |
Biotechnology | 0.14% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
Annual Asset Resilience Ratio for Merus BV (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Merus BV.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 31.04% | $243.73 Million | $785.13 Million | -1.92pp |
| 2023-12-31 | 32.96% | $150.13 Million | $455.49 Million | -4.88pp |
| 2022-12-31 | 37.84% | $142.48 Million | $376.54 Million | +0.83pp |
| 2021-12-31 | 37.01% | $168.99 Million | $456.60 Million | +17.69pp |
| 2020-12-31 | 19.32% | $44.67 Million | $231.22 Million | +3.32pp |
| 2019-12-31 | 16.00% | $42.15 Million | $263.38 Million | -4.52pp |
| 2018-12-31 | 20.53% | $51.31 Million | $249.96 Million | +3.23pp |
| 2017-12-31 | 17.30% | $40.84 Million | $236.11 Million | -52.65pp |
| 2013-12-31 | 69.95% | $12.00 Million | $17.16 Million | -- |
About Merus BV
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the… Read more